Sanjukta Bhattacharya is Co-Founder at Atlas Discovery (YC S26), a TechBio startup building foundation models of patient drug response to predict clinical trial outcomes.

Sanjukta studied AI at the University of Bristol as a PhD student and previously conducted independent research at Los Alamos National Laboratory (LANL) in New Mexico.

She is deeply passionate about the intersection of network biology and AI architectures, with a focus on gene expression and discrete diffusion models for clinical prediction.

Atlas Discovery is backed by Y Combinator, Pear VC, and Glasswing Ventures, and has presented research at top conferences including ICLR, CSHL, and ICML.

The company's models have demonstrated 70-90% accuracy in separating drug responders from non-responders across Cancer and Autoimmune disease trials, representing over 10x improvement in accuracy while training on 50x less data.